Bladder Cancer Molecular Subtyping via RT-qPCR Biomarker Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating bladder cancer are inadequate, particularly for non-muscle-invasive and muscle-invasive types, as they lack reliable, objective, and quantitative tools for molecular subtyping, leading to inaccurate treatment selection and poor prognosis prediction.
Innovation Solution
An in vitro method that determines the expression levels of specific RNA transcripts, such as HER2, ESR1, PGR, Ki67, and RACGAP1, to identify molecular subtypes of bladder cancer, enabling personalized treatment regimens through RT-qPCR-based kits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional clinicopathological methods are used for bladder cancer diagnosis and treatment selection, then the diagnostic process is simple and widely applicable, but the accuracy of molecular subtyping and prognosis prediction is insufficient
Solution Approach 1:
The diagnostic method is segmented into distinct molecular marker assessments (e.g., HER2, ESR1, PGR, Ki67, RACGAP1) that can be performed independently through RT-qPCR. This allows the complex diagnostic process to be divided into manageable components, each contributing to the overall molecular subtype classification while maintaining systematic organization.
Solution Approach 2:
The patent replaces conventional mechanical/histological examination methods with molecular biology-based RT-qPCR technology. This substitution enables quantitative measurement of gene expression levels, providing objective and precise molecular subtyping that overcomes the limitations of subjective histopathological evaluation.
2Reliability
If current treatment standards are applied to all bladder cancer patients, then the treatment approach is uniform and easy to implement, but the treatment effectiveness is inadequate for heterogeneous tumor types
Solution Approach 1:
The patent enables treatment customization by identifying specific molecular characteristics (local qualities) of individual tumors through marker assessment. Patients receive treatment regimens tailored to their specific molecular subtype (e.g., luminal A, luminal B, HER2-enriched, basal-like), ensuring that each patient receives the most appropriate therapy for their tumor's unique molecular profile.
Solution Approach 2:
The diagnostic system measures multiple molecular parameters (gene expression levels of HER2, ESR1, PGR, Ki67, RACGAP1) to classify tumors into distinct molecular subtypes. These parameter changes enable differentiation between tumor types that would appear identical under conventional classification, allowing for parameter-based treatment optimization.
3Measurement precision
If superficial bladder cancer patients undergo lifelong surveillance and standard treatment, then the treatment protocol is established and standardized, but the high recurrence rate and undertreatment of 30% of patients persist
Solution Approach 1:
The molecular subtyping is performed preliminarily at the time of initial diagnosis, before treatment decisions are made. This preliminary molecular characterization allows clinicians to identify high-risk patients who require more aggressive initial therapy or intensified surveillance, rather than waiting for recurrence to occur during lifelong monitoring.
Solution Approach 2:
The molecular marker assessment provides immediate feedback on tumor biology and recurrence risk, enabling real-time adjustment of treatment intensity and surveillance frequency. High-risk molecular subtypes trigger more aggressive treatment protocols, while low-risk subtypes allow for conservative management, optimizing resource utilization.
4Reliability
If muscle-invasive bladder cancer patients receive radical cystectomy with perioperative chemotherapy, then the treatment is aggressive and potentially curative, but the high rate of clinical understaging results in inadequate treatment for some patients
Solution Approach 1:
The patent replaces conventional anatomical staging with molecular profiling to assess tumor aggressiveness and guide treatment decisions. Molecular subtyping provides a functional assessment of tumor biology that complements anatomical staging, enabling more accurate prediction of treatment response and recurrence risk.
Solution Approach 2:
Molecular markers serve as intermediaries between anatomical staging and treatment selection. The molecular profile (luminal A, luminal B, HER2-enriched, basal-like) acts as a mediator that translates tumor characteristics into treatment recommendations, bridging the gap between staging and therapeutic decision-making.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a reliable and reproducible method for stratifying bladder cancer patients, improving treatment outcomes by predicting recurrence-free survival, progression-free survival, and disease-specific survival, and guiding optimal therapeutic procedures.
Implementation Method 1
determining the expression level of RNA transcript of at least one gene selected from the group consisting of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ESR1), progesterone receptor (PGR), proliferation antigen Ki-67 (Ki67) and RacGTPase-activating protein 1 (RACGAP1) in a sample of the tumor
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to in vitro methods of identifying a molecular subtype of a tumor in a patient having bladder cancer and to methods of stratifying a bladder cancer patient for tumor treatment. It further relates to corresponding kits and their uses, as well as to prognostic biomarkers for bladder cancer, in particular singular prognostic biomarkers.